References
- Valade et al. UNAIDS Data. UNAIDS. 2014. PMC4023733. [cited 2020 May 1]. Available from: https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf
- Bouazza et al. B Antiretroviral therapy has saved millions of lives from AIDS and could save more. 2014. PMC4239978.
- Calcagno et al. Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrol Dial Transplant. 2013;30(10):1734–1740. PMC3623307. DOI:https://doi.org/10.1093/ndt/gfv207.• This paper offers data and insights on HIV prevalence in US patients with ESKD
- Scholler-Gyure et al. HIV-1 and HIV-Associated Nephropathy 25 Years Later. Clin J Am Soc Nephrol. 2009;2(Suppl 1):S20–4. DOI:https://doi.org/10.2165/10895940-000000000-00000
- Rathbun et al. Update on current management of chronic kidney disease in patients with HIV infection. Int J Nephrol Renovasc Dis. 2006;9:223–234. DOI:https://doi.org/10.2147/IJNRD.S93887. DOI:https://doi.org/10.2174/138161206776055840 •• This is a comprehensive understanding and management of HIV infection among those with chronic kidney disease
- Kudose S, Santoriello D, Bomback AS, et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int. 2020;97:1006–1016. DOI:https://doi.org/10.1016/j.kint.2020.01.018• This is a recent and extensive study covering the broad range of HIV-associated kidney disease seen generally on histopathology
- Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2005;40(11):1559–1585.
- Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol. 2008;28(3):478–486. DOI:https://doi.org/10.1159/000112851.
- Wyatt CM, Morgello S, Katz-Malamed R, et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009;75(4):428–434. DOI:https://doi.org/10.1038/ki.2008.604.
- Swanepoel CR, Atta MG, D’Agati VD, et al. Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2018;93(3):545–559.
- Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;59(9):e96–138.•• This is a comprehensive management of HIV infection among those with chronic kidney disease
- Gupta SK, Mamlin BW, Johnson CS, et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol. 2004;61(1):1–6.
- Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal HIV-1 infection. J Int AIDS Soc. 2013;16:18596.
- Ray PE. Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy. Pediatr Nephrol. 2009;24(11):2109–2119.
- Yahaya I, Uthman AO, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev. 2013;4:CD007183.
- Smith MC, Pawar R, Carey JT, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med. 1994;97(2):145–151. DOI:https://doi.org/10.1016/0002-9343(94)90024-8.
- Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med. 1996;101(1):41–48. DOI:https://doi.org/10.1016/S0002-9343(96)00065-4.
- Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis. 1996;28(2):202–208.
- Burns GC, Paul SK, Toth IR, et al. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol. 1997;8(7):1140–1146.
- Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 2003;64(4):1462–1471.
- Bige N, Lanternier F, Viard JP, et al. Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol Dial Transplant. 2012;27(3):1114–1121. DOI:https://doi.org/10.1093/ndt/gfr376.
- Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004;18(3):541–546. DOI:https://doi.org/10.1097/00002030-200402200-00022.• This paper documents our understanding of HIVAN over the course of several years.
- Alfano G, Cappelli G, Fontana F, et al. Kidney Disease in HIV infection. J Clin Med. 2019;8:8.
- Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006;21(10):2809–2813. DOI:https://doi.org/10.1093/ndt/gfl337.
- Fabian J, Naicker S, Goetsch S, et al. The clinical and histological response of HIV-associated kidney disease to antiretroviral therapy in South Africans. Nephrol Dial Transplant. 2013;28(6):1543–1554.
- Achhra AC, Mocroft A, Ross M, et al. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. Int J Antimicrob Agents. 2017;50(3):453–460. DOI:https://doi.org/10.1016/j.ijantimicag.2017.04.021.
- Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60(6):941–949. DOI:https://doi.org/10.1093/cid/ciu919.
- Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Sci. 2010;329(5993):841–845. DOI:https://doi.org/10.1126/science.1193032.
- Atta MG, Estrella MM, Kuperman M, et al., HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int. 82(3): 338–343. 2012. . doi:https://doi.org/10.1038/ki.2012.111.• This paper offers a very succinct yet comprehensive understanding of the pathological findings associated with APOL1 and HIVAN
- Fine DM, Wasser WG, Estrella MM, et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol. 2012;23(2):343–350. DOI:https://doi.org/10.1681/ASN.2011060562.
- Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int. 2013;84(4):834–840. DOI:https://doi.org/10.1038/ki.2013.203.
- O’Toole JF, Bruggeman LA, Sedor JR. APOL1 and proteinuria in the AASK: unraveling the pathobiology of APOL1. Clin J Am Soc Nephrol. 2017;12(11):1723–1725.
- Freedman BI, Murea M. Target organ damage in African American hypertension: role of APOL1. Curr Hypertens Rep. 2012;14(1):21–28.
- Langefeld CD, Divers J, Pajewski NM, et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the systolic blood pressure intervention trial. Kidney Int. 2015;87(1):169–175. DOI:https://doi.org/10.1038/ki.2014.254.
- Grams ME, Rebholz CM, Chen Y, et al. Race, APOL1 risk, and eGFR decline in the general population. J Am Soc Nephrol. 2016;27(9):2842–2850. DOI:https://doi.org/10.1681/ASN.2015070763.
- Aghajan M, Booten SL, Althage M, et al. Antisense oligonucleotide treatment ameliorates IFN-gamma-induced proteinuria in APOL1-transgenic mice. JCI Insight. 2019;4:12.
- Foy MC, Estrella MM, Lucas GM, et al., Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy. Clin J Am Soc Nephrol. 8(9): 1524–1532. 2013. . doi:https://doi.org/10.2215/CJN.10991012.•• This paper documents our recent understanding of the development and possible predictors of HIVAN and HIVICK
- Nobakht E, Cohen SD, Rosenberg AZ, et al. HIV-associated immune complex kidney disease. Nat rev Nephrol. 2016;12(5):291–300. DOI:https://doi.org/10.1038/nrneph.2015.216.•• This is a recent and extensive review covering the broad range of HIVICK
- Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases. Kidney Int. 2005;67(4):1381–1390.
- Schectman JM, Kimmel PL. Remission of hepatitis B-associated membranous glomerulonephritis in human immunodeficiency virus infection. Am J Kidney Dis. 1991;17(6):716–718.
- Stokes MB, Chawla H, Brody RI, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis. 1997;29(4):514–525. DOI:https://doi.org/10.1016/S0272-6386(97)90332-2.
- Chidambaram M, Stigant CE, Sugar LM, et al. Type I membranoproliferative glomerulonephritis in an HIV-infected individual without hepatitis C co-infection. Clin Nephrol. 2002;57(2):154–157.
- Martin JL, Thomas D, Colindres RE. Immunotactoid glomerulopathy in an HIV-positive African-American man. Am J Kidney Dis. 2003;42(6):E6–10.
- Chen C, Jhaveri KD, Hartono C, et al. An uncommon glomerular disease in an HIV patient: value of renal biopsy and review of the literature. Clin Nephrol. 2011;75(1):80–88.
- Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. HIV-associated immune-mediated renal disease. Kidney Int. 1993;44(6):1327–1340.
- Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66(3):1145–1152. DOI:https://doi.org/10.1111/j.1523-1755.2004.00865.x.
- Booth JW, Hamzah L, Jose S, et al. Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Nephrol Dial Transplant. 2016;31(12):2099–2107. DOI:https://doi.org/10.1093/ndt/gfv436.
- Bird JE, Durham SK, Giancarli MR, et al. Captopril prevents nephropathy in HIV-transgenic mice. J Am Soc Nephrol. 1998;9(8):1441–1447.
- Kumar D, Plagov A, Yadav I, et al. Inhibition of renin activity slows down the progression of HIV-associated nephropathy. Am J Physiol Renal Physiol. 2012;303(5):F711–20. DOI:https://doi.org/10.1152/ajprenal.00643.2011.
- Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004;39(Suppl 5):S267–75. DOI:https://doi.org/10.1086/422363.
- Bade NA, Giffi VS, Baer MR, et al. Thrombotic microangiopathy in the setting of human immunodeficiency virus infection: High incidence of severe thrombocytopenia. J Clin Apher. 2018;33(3):342–348. DOI:https://doi.org/10.1002/jca.21615.• This is a succint and informative study on TMA and its effects in HIV patients
- Ucar A, Fernandez HF, Byrnes JJ, et al. Thrombotic microangiopathy and retroviral infections: a 13-year experience. Am J Hematol. 1994;45(4):304–309.
- Leaf AN, Laubenstein LJ, Raphael B, et al. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-1) infection. Ann Intern Med. 1988;109(3):194–197.
- Evans MW, Vaughan LB, Giffi VS, et al. Rituximab treatment for thrombotic thrombocytopenic purpura associated with human immunodeficiency virus failing extensive treatment with plasma exchange: a report of two cases. AIDS Patient Care STDS. 2010;24(6):349–352.
- Selvaraj S, Ghebremichael M, Li M, et al. Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase-gamma inhibition. Clin Pharmacol Ther. 2014;96(1):110–120. DOI:https://doi.org/10.1038/clpt.2014.64.
- Scherzer R, Estrella M, Li Y, et al., Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 26(7): 867–875. 2012. doi:https://doi.org/10.1097/QAD.0b013e328351f68f.• This paper documents our understanding of tenofovir and its nephrotoxicity
- Borges AH, Hoy J, Florence E, et al. Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. Clin Infect Dis. 2017;64(10):1413–1421. DOI:https://doi.org/10.1093/cid/cix167.
- Sax PE, Wohl D, Yin MT, et al., Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 385(9987): 2606–2615. 2015. . doi:https://doi.org/10.1016/S0140-6736(15)60616-X.• This study presents good information on the outcomes of TDF and TAF
- Suzuki S, Nishijima T, Kawasaki Y, et al. Effect of Tenofovir Disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-naive Asian patients: results from 12-year observational cohort. AIDS Patient Care STDS. 2017;31(3):105–112. DOI:https://doi.org/10.1089/apc.2016.0286.
- Quesada PR, Esteban LL, Garcia JR, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37(5):865–872. DOI:https://doi.org/10.1007/s11096-015-0132-1.
- Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37(12):e174–6. DOI:https://doi.org/10.1086/379829.
- Hamzah L, Jose S, Booth JW, et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. J Infect. 2017;74(5):492–500. DOI:https://doi.org/10.1016/j.jinf.2017.01.010.
- Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42(2):283–290.
- Waheed S, Attia D, Estrella MM, et al. Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series. Clin Kidney J. 2015;8(4):420–425. DOI:https://doi.org/10.1093/ckj/sfv041.
- Hoy JF, Grund B, Roediger M, et al. Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial. J Bone Miner Res. 2017;32(9):1945–1955. DOI:https://doi.org/10.1002/jbmr.3183.
- Hoy J, Grund B, Roediger M, et al. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: the SMART body composition substudy. J Bone Miner Res. 2013;28(6):1264–1274. DOI:https://doi.org/10.1002/jbmr.1861.
- Atta MG, De Seigneux S, Lucas GM. Clinical pharmacology in HIV therapy. Clin J Am Soc Nephrol. 2019;143:435–444. 2019. doi:https://doi.org/10.2215/CJN.02240218
- Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–455. DOI:https://doi.org/10.1097/QAI.0b013e3182965d45.
- Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687–692.
- Novick TK, Choi MJ, Rosenberg AZ, et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. Medicine (Baltimore). 2017;96(36):e8046.
- Rathbun RC, Lockhart SM, Stephens JR. Current HIV treatment guidelines–an overview. Curr Pharm Des. 2006;12(9):1045–1063.
- Menez S, Hanouneh M, McMahon BA, et al. Pharmacotherapy and treatment options for HIV-associated nephropathy. Expert Opin Pharmacother. 2018;19(1):39–48. DOI:https://doi.org/10.1080/14656566.2017.1416099.• This is a recent and extensive review covering treatment options for HIV-associated kidney diseases
- Parkhie SM, Fine DM, Lucas GM, et al. Characteristics of patients with HIV and Biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol. 2010;5(5):798–804.• This paper offers a very succinct yet comprehensive understanding of the pathological findings associated with institial nephritis among patients with HIV
- Sawinski D. ESRD patients coinfected with human immunodeficiency virus and Hepatitis C: outcomes and management challenges. Semin Dial. 2019;32(2):159–168.
- Crum-Cianflone N, Quigley M, Utz G, et al. BK virus-associated renal failure among HIV patients. Aids. 2007;21:1501–1502. [ England].
- Frazao JM, Elangovan L, Felsenfeld AJ, et al. Epstein-Barr-virus-induced interstitial nephritis in an HIV-positive patient with progressive renal failure. Nephrol dialysis trans. 1998;13(7):1849–1852.
- Mazoyer E, Daugas E, Verine J, et al. A case report of adenovirus-related acute interstitial nephritis in a patient with AIDS. Am J Kidney Dis. 2008;51(1):121–126. DOI:https://doi.org/10.1053/j.ajkd.2007.08.025.
- Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000;58(3):1253–1260.
- Briggs WA, Tanawattanacharoen S, Choi MJ, et al. Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy. Am J Kidney Diseases. 1996;28(4):618–621.
- Kodner CM, Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am Fam Physician. 2003;67(12):2527–2534.
- Zaidan M, Lescure FX, Brochériou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the Past 15 Years: a clinico-pathological study. Clin J Am Soc Nephrol. 2013;8(6):930–938.
- Izzedine H, M B M, Bardier A, et al. Atazanavir crystal nephropathy. AIDS. 2007;21(17):2357–2358.
- Hara M, Suganuma A, Yanagisawa N, et al. Atazanavir nephrotoxicity. Clin Kidney J. 2015;8(2):137–142.
- Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127(2):119–125. DOI:https://doi.org/10.7326/0003-4819-127-2-199707150-00004.
- Dieleman JP, van der Feltz M, Bangma CH, et al. Papillary necrosis associated with the HIV protease inhibitor indinavir. Infection. 2001;29(4):232–233.
- Shahinian V, Rajaraman S, Borucki M, et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis. 2000;35(5):884–888.
- Nishijima T, Tsuchiya K, Tanaka N, et al. Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3ʹ untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. J Antimicrob Chemother. 2014;69(12):3320–3328. DOI:https://doi.org/10.1093/jac/dku304.
- Ekrikpo UE, Kengne AP, Bello AK, et al., Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One. 13(4): e0195443. 2018. . doi:https://doi.org/10.1371/journal.pone.0195443.•• This is an extensive review covering the broad range of HIV-associated kidney disease affecting patients globally
- Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743. DOI:https://doi.org/10.1016/S0140-6736(12)61853-4.
- Ciccacci F, Tolno VT, Doro Altan AM, et al. Noncommunicable diseases burden and risk factors in a cohort of HIV+ elderly patients in Malawi. AIDS Res Hum Retroviruses. 2019;35(11–12):1106–1111. DOI:https://doi.org/10.1089/aid.2019.0125.
- Achwoka D, Waruru A, Chen TH, et al. Noncommunicable disease burden among HIV patients in care: a national retrospective longitudinal analysis of HIV-treatment outcomes in Kenya, 2003-2013. BMC Public Health. 2019;19(1):372. DOI:https://doi.org/10.1186/s12889-019-6716-2.
- Smit M, Olney J, Ford NP, et al. The growing burden of noncommunicable disease among persons living with HIV in Zimbabwe. AIDS. 2018;32(6):773–782. DOI:https://doi.org/10.1097/QAD.0000000000001754.
- Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179–1184. DOI:https://doi.org/10.1001/archinte.165.10.1179.
- Samad F, Harris M, Puskas CM, et al. Incidence of diabetes mellitus and factors associated with its development in HIV-positive patients over the age of 50. BMJ Open Diabetes Res Care. 2017;5(1):e000457. DOI:https://doi.org/10.1136/bmjdrc-2017-000457.
- De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224–1229. DOI:https://doi.org/10.2337/dc07-2013.
- Lien LF, Feinglos MN. Protease inhibitor-induced diabetic complications: incidence, management and prevention. Drug Saf. 2005;28(3):209–226.
- Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e44454. DOI:https://doi.org/10.1371/journal.pone.0044454.
- Atta MG, Fine DM, Kirk GD, et al. Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin Infect Dis. 2007;45(12):1625–1632.
- Rodriguez RA, Mendelson M, O’Hare AM, et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol. 2003;14(5):1307–1313.
- Butt AA, Khan UA, Skanderson M. Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis. J Clin Gastroenterol. 2008;42(9):1054–1059.
- Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13(7):1889–1893.
- Ndlovu KC, Sibanda W, Assounga A. Peritonitis outcomes in patients with HIV and end-stage renal failure on peritoneal dialysis: a prospective cohort study. BMC Nephrol. 2017;18(1):48.
- Tourret J, Tostivint I, Du Montcel ST, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol. 2006;1(6):1241–1247. DOI:https://doi.org/10.2215/CJN.02211205.
- Trullas JC, Cofan F, Barril G, et al. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr. 2011;57(4):276–283. DOI:https://doi.org/10.1097/QAI.0b013e318221fbda.
- Izzedine H, Launay-Vacher V, Deray G. Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis. Kidney Int. 2003;64(6):2324. DOI:https://doi.org/10.1046/j.1523-1755.2003.341_3.x
- Szczech LA, et al. The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis. Kidney Int. 2003;63(6):2295–2301
- Izzedine H, et al. Pharmacokinetics of tenofovir in haemodialysis. Nephrol Dial Transplant. 2003;18(9):1931–1933. DOI:https://doi.org/10.1093/ndt/gfg327
- Gupta SK, Rosenkranz SL, Cramer YS, et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 2008;22:1919–1927.
- Cramer YS, Rosenkranz SL, Hall SD, et al. Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177. J Acquir Immune Defic Syndr. 2010;54:e7–9.
- Aleman J, van den Berk GE, Franssen EJ, et al. Tenofovir disoproxil treatment for a HIV-hepatitis B virus coinfected patient undergoing peritoneal dialysis: which dose do we need?. AIDS. 2015;29:1579–1580.
- Slaven JE, Decker BS, Kashuba ADM, et al. Plasma and intracellular concentrations in HIV-infected patients requiring hemodialysis dosed with Tenofovir Disoproxil fumarate and emtricitabine. J Acquir Immune Defic Syndr. 2016;73:e8–e10.
- Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation. 1998;65(9):1187–1191.
- Alameddine M, Jue JS, Zheng I, et al. Challenges of kidney transplantation in HIV positive recipients. Transl Androl Urol. 2019;8(2):148–154.
- Ebpg E, Renal A, European Society for Organ T. European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant. 2000;15(Suppl 7):1–85.• This is a good review of the guidelines from the European Society on kidney transplantations
- Yoon SC, Hurst FP, Jindal RM, et al. Trends in renal transplantation in patients with human immunodeficiency virus infection: an analysis of the United States renal data system. Transplantation. 2011;91(8):864–868. DOI:https://doi.org/10.1097/TP.0b013e31820f081f.
- Locke JE, Gustafson S, Mehta S, et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg. 2017;265(3):604–608. DOI:https://doi.org/10.1097/SLA.0000000000001761.
- Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355–365. DOI:https://doi.org/10.1111/j.1600-6143.2007.02061.x.
- Arnold E. The HIV organ policy equity act: offering hope to individuals with end stage renal disease and HIV. Nephrol Nurs J. 2017;44(3):230–249.•• This paper demonstrates some of the early treatment of kidney transplantation to patients with HIV and ESKD
- Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–2014. DOI:https://doi.org/10.1056/NEJMoa1001197.
- Waheed S, Sakr A, Chheda ND, et al. Outcomes of renal transplantation in HIV-1 associated nephropathy. PLoS One. 2015;10(6):e0129702. DOI:https://doi.org/10.1371/journal.pone.0129702.
- Zicari S, Sessa L, Cotugno N, et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019;11:3.
- Canaud G, Dejucq-Rainsford N, Avettand-Fenoel V, et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol. 2014;25(2):407–419. DOI:https://doi.org/10.1681/ASN.2013050564.
- Avettand-Fenoel V, Rouzioux C, Legendre C, et al. HIV infection in the native and Allograft kidney: implications for management, diagnosis, and transplantation. Transplantation. 2017;101(9):2003–2008.
- Freedman BI, Pastan SO, Israni AK, et al. APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplant. 2016;100(1):194–202. DOI:https://doi.org/10.1097/TP.0000000000000969.
- Primeggia J, Timpone JG Jr., Kumar PN. Pharmacologic issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):473–486.
- Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7(12):2816–2820. DOI:https://doi.org/10.1111/j.1600-6143.2007.02007.x.
- Azar MM, Malinis MF, Moss J, et al. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. Int J STD AIDS. 2017;28(5):447–458.
- Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS society-USA panel. JAMA. 2010;304(3):321–333. DOI:https://doi.org/10.1001/jama.2010.1004.
- Atta MG, Estrella MM, Skorecki KL, et al. Association of APOL1 Genotype with Renal Histology among Black HIV-positive patients undergoing kidney biopsy. Clin J Am Soc Nephrol. 2016;11(2):262–270. DOI:https://doi.org/10.2215/CJN.07490715.
- Saulsbury F. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis. 2001;32:464–468.
- van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatr. 2002;110:e19.
- Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21:1034–1036.
- Vigano A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig. 2007;27:573–581.
- Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28:619–625.
- Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24:525–534.
- Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25:171–176.
- Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig. 2011;31:407–415.
- Della Negra M, de Carvalho AP, de Aquino MZ, et al. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012;31:469–473.
- Lankisch P, Laws HJ, Wingen AM, et al. Association of nephrotic syndrome with immune reconstitution inflammatory syndrome. Pediatr Nephrol. 2012;27:667–669.
- Pontrelli G, Cotugno N, Amodio D, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. BMC Infect Dis. 2012;12:18.
- Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32:495–500.
- Della Negra M, De Carvalho AP, De Aquino MZ, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321. Pediatr Infect Dis J. 2015;34:398–405.
- Lafaurie M, De Sousa B, Ponscarme D, et al. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study. PLoS One. 2014;9:e112836.
- Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol. 1999;161:1082–1084.
- Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207:1359–1369.
- Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63:96–100.